A phase I study enrolling 15 dogs with B-cell lymphoma tested a therapy with a combination of autologous tumor antigen-coated microbeads (large multivalent immunogen—LMI) with cytokine therapy including IL-2 and GM-CSF, following induction of remission with conventional chemotherapy. Here, CSF2 is linked to neoplasm.